RESUMEN
Drug resistance of Klebsiella pneumoniae severely threatens human health. Overcoming the mechanisms of K. pneumoniae resistance to develop novel vaccines against drug-resistant K. pneumoniae is highly desired. Here, we report a technology platform that uses high pressure to drive drug-resistant K. pneumoniae to pass through a gap, inducing the formation of stable artificial bacterial biomimetic vesicles (BBVs). These BBVs had little to no bacterial intracellular protein or nucleic acid and had high yields. BBVs were efficiently taken up by dendritic cells to stimulate their maturation. BBVs as K. pneumoniae vaccines had the dual functions of inducing bacteria-specific humoral and cellular immune responses to increase animals' survival rate and reduce pulmonary inflammation and bacterial loads. We believe that BBVs are new-generation technology for bacterial vesicle preparation. Establishment of this BBV vaccine platform can maximally expand preparation technology for vaccines against drug-resistant K. pneumoniae.
Asunto(s)
Vacunas Bacterianas/uso terapéutico , Materiales Biomiméticos/uso terapéutico , Vesículas Extracelulares/inmunología , Infecciones por Klebsiella/terapia , Klebsiella pneumoniae/inmunología , Animales , Vacunas Bacterianas/síntesis química , Vacunas Bacterianas/inmunología , Vacunas Bacterianas/toxicidad , Materiales Biomiméticos/síntesis química , Materiales Biomiméticos/toxicidad , Fraccionamiento Celular/métodos , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Femenino , Inmunidad Celular/efectos de los fármacos , Inmunidad Humoral/efectos de los fármacos , Klebsiella pneumoniae/química , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , PresiónRESUMEN
This study dealt with the toxicity of inactivated bacteria intended for veterinary autogenous vaccines toward a suitable control assay. Two in vitro methods were used. The [3-(4, 5 -dimethylthiazol-2-yl) -2,5 -diphenyltetrazolium bromide] (MTT) test, based on the metabolic reaction of a tetrazolium salt in vital cells, was adopted on the basis of previous positive results. The Interleukin (IL)-1 beta release assay on monocyte-derived pig macrophages was carried out for comparative purposes, to evaluate the possible role of the inflammatory response. MTT and IL-1 beta responses showed a significant correlation (P < 0.05) at defined test dilutions of bacterial antigens, whereas no correlation was demonstrated using MTT responses normalized on bacterial cell concentration. Furthermore, the toxic effects shown in the MTT test were positively correlated to the extracellular protein content. On the whole, the above results could be a useful basis for the development of a toxicity assay on inactivated bacterial vaccines. Also, our data point at bacterial autolysis as a major component underlying toxicity.
Asunto(s)
Vacunas Bacterianas/toxicidad , Macrófagos/efectos de los fármacos , Sus scrofa/fisiología , Pruebas de Toxicidad , Animales , Técnicas In Vitro , Sales de Tetrazolio/química , Tiazoles/química , Vacunas de Productos Inactivados/toxicidadRESUMEN
Approximately one-third of the reportable USDA Category D and E laboratory animals in the United States are expended on the potency testing of leptospiral vaccines by the codified hamster vaccination-challenge assay. Valid tests require ≥80% of challenge controls to succumb to disease and an LD50 between 10 and 10,000. This work evaluates the risk associated with the removal of LD50 limits; thereby, eliminating back-titration hamsters from in vivo potency assays for Leptospira (L.) serogroups Canicola and Icterohaemorrhagiae. The impact was assessed through 1) retrospective analysis of industry and CVB serial release data from July 2011-April 2015 and 2) evaluation through vaccination-challenge assays. For the initial vaccination-challenge assays (nâ¯=â¯3/serogroup), one group received potent bacterin (PB) and six groups received subpotent bacterins (SB1-SB6). PB and SB1 were challenged with a single dilution of Leptospira between 10 and 10,000 LD50. SB2-SB6 received serial dilutions of more concentrated challenge. Based on the retrospective analysis and in vivo assays, 80% of the challenge controls succumbing to disease reasonably ensured the minimal LD50 was administered. Subpotent vaccines were not at increased risk for being deemed potent when challenged with >10,000 LD50, but potent vaccines were at risk of being deemed subpotent when challenged with >10,000 LD50.
Asunto(s)
Vacunas Bacterianas/inmunología , Leptospira interrogans serovar canicola/inmunología , Leptospira interrogans serovar icterohaemorrhagiae/inmunología , Leptospirosis/veterinaria , Vacunación/veterinaria , Potencia de la Vacuna , Drogas Veterinarias/inmunología , Bienestar del Animal , Animales , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/toxicidad , Cricetinae , Leptospirosis/prevención & control , Dosificación Letal Mediana , Estudios Retrospectivos , Estados Unidos , Drogas Veterinarias/administración & dosificación , Drogas Veterinarias/toxicidadRESUMEN
BACKGROUND: Pasteurella multocida B:2 causes bovine haemorrhagic septicaemia (HS), leading to rapid fatalities in cattle and buffaloes. An attenuated derivative of P. multocida B:2 GDH7, was previously constructed through mutation of the gdhA gene and proved to be an effective live attenuated vaccine for HS. Currently, only two potential live attenuated vaccine candidates for HS are being reported; P. multocida B:2 GDH7 and P. multocida B:2 JRMT12. This study primarily aims to investigate the potential of P. multocida B:2 GDH7 strain as a delivery vehicle for DNA vaccine for future multivalent applications. RESULTS: An investigation on the adherence, invasion and intracellular survival of bacterial strains within the bovine aortic endothelial cell line (BAEC) were carried out. The potential vaccine strain, P. multocida B:2 GDH7, was significantly better (p ≤ 0.05) at adhering to and invading BAEC compared to its parent strain and to P. multocida B:2 JRMT12 and survived intracellularly 7 h post treatment, with a steady decline over time. A dual reporter plasmid, pSRGM, which enabled tracking of bacterial movement from the extracellular environment into the intracellular compartment of the mammalian cells, was subsequently transformed into P. multocida B:2 GDH7. Intracellular trafficking of the vaccine strain, P. multocida B:2 GDH7 was subsequently visualized by tracking the reporter proteins via confocal laser scanning microscopy (CLSM). CONCLUSIONS: The ability of P. multocida B:2 GDH7 to model bactofection represents a possibility for this vaccine strain to be used as a delivery vehicle for DNA vaccine for future multivalent protection in cattle and buffaloes.
Asunto(s)
Vacunas Bacterianas , Enfermedades de los Bovinos/prevención & control , Endotelio Vascular/microbiología , Septicemia Hemorrágica/veterinaria , Pasteurella multocida/fisiología , Animales , Aorta/citología , Aorta/microbiología , Adhesión Bacteriana , Vacunas Bacterianas/genética , Vacunas Bacterianas/toxicidad , Bovinos , Enfermedades de los Bovinos/microbiología , Células Cultivadas , Septicemia Hemorrágica/prevención & control , Pasteurella multocida/genética , Vacunas Atenuadas/genética , Vacunas Atenuadas/toxicidad , Vacunas de ADN/toxicidadRESUMEN
An efficient technique for evaluation of the quality control of vaccines against clostridiosis is described in this study. This technique is capable of quantifying the toxoid of the bacterium Clostridium perfringens Type D, which is commonly found within these vaccines. The described method is performed in vivo to quantify the toxoid, replacing the current predominant approaches that use the titration of toxins before the inactivation process. This method is based on the partial neutralization of a determined dose of antitoxin by testing different doses of the toxoid. In order to guarantee its reliability, it is essential for the technique to be validated. Thus, the technique was tested using the following validation parameters: specificity and selectivity, detection limit, linear correlation, precision and robustness, in agreement with the requirements of regulatory agencies and international committees from around the world. The method was found to be specific, selective, robust, precise, and linear inside a specific concentration range. Therefore, it could be applied to the quality control of clostridiosis vaccines with satisfactory results.
Asunto(s)
Vacunas Bacterianas/inmunología , Vacunas Bacterianas/normas , Infecciones por Clostridium/inmunología , Clostridium perfringens/inmunología , Control de Calidad , Animales , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Toxinas Bacterianas/inmunología , Vacunas Bacterianas/toxicidad , Infecciones por Clostridium/prevención & control , Clostridium perfringens/patogenicidad , Femenino , Ratones , Modelos Animales , Pruebas de Neutralización/métodos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Vacunas de Productos InactivadosRESUMEN
BACKGROUND: Bovine necrohemorrhagic enteritis is caused by Clostridium perfringens type A. Due to the rapid progress and fatal outcome of the disease, vaccination would be of high value. In this study, C. perfringens toxins, either as native toxins or after formaldehyde inactivation, were evaluated as possible vaccine antigens. We determined whether antisera raised in calves against these toxins were able to protect against C. perfringens challenge in an intestinal loop model for bovine necrohemorrhagic enteritis. RESULTS: Alpha toxin and perfringolysin O were identified as the most immunogenic proteins in the vaccine preparations. All vaccines evoked a high antibody response against the causative toxins, alpha toxin and perfringolysin O, as detected by ELISA. All antibodies were able to inhibit the activity of alpha toxin and perfringolysin O in vitro. However, the antibodies raised against the native toxins were more inhibitory to the C. perfringens-induced cytotoxicity (as tested on bovine endothelial cells) and only these antibodies protected against C. perfringens challenge in the intestinal loop model. CONCLUSION: Although immunization of calves with both native and formaldehyde inactivated toxins resulted in high antibody titers against alpha toxin and perfringolysin O, only antibodies raised against native toxins protect against C. perfringens challenge in an intestinal loop model for bovine necrohemorrhagic enteritis.
Asunto(s)
Anticuerpos Neutralizantes/inmunología , Toxinas Bacterianas/administración & dosificación , Vacunas Bacterianas/administración & dosificación , Proteínas de Unión al Calcio/administración & dosificación , Enfermedades de los Bovinos/microbiología , Infecciones por Clostridium/veterinaria , Clostridium perfringens/inmunología , Enteritis/veterinaria , Proteínas Hemolisinas/administración & dosificación , Fosfolipasas de Tipo C/administración & dosificación , Animales , Toxinas Bacterianas/inmunología , Toxinas Bacterianas/toxicidad , Vacunas Bacterianas/inmunología , Vacunas Bacterianas/toxicidad , Proteínas de Unión al Calcio/inmunología , Proteínas de Unión al Calcio/toxicidad , Bovinos , Enfermedades de los Bovinos/inmunología , Enfermedades de los Bovinos/prevención & control , Infecciones por Clostridium/inmunología , Infecciones por Clostridium/patología , Infecciones por Clostridium/prevención & control , Modelos Animales de Enfermedad , Células Endoteliales/inmunología , Enteritis/inmunología , Enteritis/patología , Enteritis/prevención & control , Proteínas Hemolisinas/inmunología , Proteínas Hemolisinas/toxicidad , Yeyuno/inmunología , Masculino , Necrosis , Fosfolipasas de Tipo C/inmunología , Fosfolipasas de Tipo C/toxicidadRESUMEN
The toxicity of Clostridium difficile large clostridial toxin B (TcdB) can be reduced by many orders of magnitude by a combination of targeted point mutations. However, a TcdB mutant with five point mutations (referred to herein as mTcdB) still has residual toxicity that can be detected in cell-based assays and in-vivo mouse toxicity assays. This residual toxicity can be effectively removed by treatment with formaldehyde in solution. Storage of the formaldehyde-treated mTcdB as a liquid can result in reversion over time back to the mTcdB level of toxicity, with the rate of reversion dependent on the storage temperature. We found that for both the "forward" mTcdB detoxification reaction with formaldehyde, and the "reverse" reversion to toxicity reaction, mouse toxicity correlated with several biochemical assays including anion exchange chromatography retention time and appearance on SDS-PAGE. Maintenance of a low concentration of formaldehyde prevents reversion to toxicity in liquid formulations. However, when samples with 0.016% (v/v) formaldehyde were lyophilized and stored at 37 °C, formaldehyde continued to react with and modify the mTcdB in the lyophilized state. Lyophilization alone effectively prevented reversion to toxicity for formaldehyde-treated, formaldehyde-removed mTcdB samples stored at 37 °C for 6 months. Formaldehyde-treated, formaldehyde-removed lyophilized mTcdB showed no evidence of reversion to toxicity, appeared stable by several assays, and was immunogenic in mice, even after storage for 6 months at 37 °C.
Asunto(s)
Proteínas Bacterianas/toxicidad , Toxinas Bacterianas/toxicidad , Vacunas Bacterianas/toxicidad , Formaldehído/metabolismo , Toxoides/toxicidad , Animales , Proteínas Bacterianas/química , Proteínas Bacterianas/inmunología , Toxinas Bacterianas/química , Toxinas Bacterianas/inmunología , Vacunas Bacterianas/química , Vacunas Bacterianas/inmunología , Vacunas Bacterianas/efectos de la radiación , Cromatografía por Intercambio Iónico , Almacenaje de Medicamentos , Electroforesis en Gel de Poliacrilamida , Femenino , Liofilización , Ratones Endogámicos C57BL , Proteínas Mutantes/química , Proteínas Mutantes/inmunología , Proteínas Mutantes/toxicidad , Temperatura , Factores de Tiempo , Toxoides/química , Toxoides/inmunologíaRESUMEN
Bioassays play central role in evaluation of biological products and those derived from bacterial toxins often rely exclusively on in vivo models for assurance of safety and potency. This chapter reviews existing regulatory approved methods designed to provide information on potency and safety of complex biological medicines with an insight into strategies considered for alternative procedures.
Asunto(s)
Toxinas Bacterianas/farmacología , Animales , Toxinas Bacterianas/normas , Toxinas Bacterianas/toxicidad , Vacunas Bacterianas/farmacología , Vacunas Bacterianas/normas , Vacunas Bacterianas/toxicidad , Bioensayo/normas , Línea Celular , HumanosRESUMEN
In this work, we produced and evaluated a vaccine based on a ß toxoid of Clostridium perfringens type C produced in Escherichia coli (rBT). The non-toxic rBT was innocuous for mice and induced 14 IU mL(-1) of ß antitoxin in rabbits, complying with the European Pharmacopeia and CFR9 - USDA guidelines.
Asunto(s)
Vacunas Bacterianas/biosíntesis , Clostridium perfringens/inmunología , Toxoides/biosíntesis , Vacunas Sintéticas/biosíntesis , Animales , Toxinas Bacterianas/genética , Vacunas Bacterianas/genética , Vacunas Bacterianas/toxicidad , Escherichia coli , Ratones , Ratones Endogámicos BALB C , Conejos , Toxoides/genética , Toxoides/toxicidad , Vacunación , Vacunas Sintéticas/genética , Vacunas Sintéticas/toxicidadRESUMEN
A recombinant botulinum vaccine (rBV A/B) is being developed to protect adults 18-55 years of age from fatal botulism caused by inhalational intoxication with botulinum neurotoxin complex (BoNT) serotype A, subtype A1 (BoNT/A1) and BoNT serotype B, subtype B1 (BoNT/B1). Fundamental to the advanced development process is an initial demonstration of product safety in animals. A comprehensive series of studies was conducted to evaluate the general toxicity, neurobehavioral toxicity and local reactogenicity of the rBV A/B vaccine prior to first use in humans. Toxicity was evaluated in CD-1 mice vaccinated with control material and three dosages of rBV A/B with or without Alhydrogel(®) by intramuscular (IM) injection on Study Days 0, 28, 56 and 70 in a volume of 100µL. Total immunizing protein given in each dose was either 0, 2, 4 or 8 µg/animal. Local reactogenicity was evaluated in mice at the dosages given and in New Zealand white (NZW) rabbits using the same injection volume (0.5 mL) and formulations (10, 20 and 40 g/mL total antigen with 0.2% (w/v) Alhydrogel(®)) intended for human use. The rBV A/B vaccine produced no apparent systemic or neurobehavioral toxicity and only transient mild inflammation at the injection site. Together these results indicated a favorable safety profile for rBV A/B and supported its use in a Phase 1 clinical trial.
Asunto(s)
Vacunas Bacterianas/toxicidad , Toxinas Botulínicas/toxicidad , Botulismo/prevención & control , Animales , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/inmunología , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Ratones , Conejos , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/toxicidadRESUMEN
Tumor-targeting bacteria have been developed as powerful anticancer agents. Salmonella typhimurium VNP20009, a representative tumor-targeting strain, has been systemically administered as a single-agent therapy at doses of 1 x 10(6) to 3 x 10(6) colony-forming unit (cfu)/mouse, or in combination with other antitumor agents at doses of 1 x 10(4) to 2 x 10(5) cfu/mouse. Recently, we reported that oral delivery of VNP20009 at the dose of 1 x 10(9) cfu/mouse induced significant anticancer effects comparable to that induced by systemic administration of this strain at 1 x 10(4) cfu/mouse. To further address the efficacy and safety of oral administration of bacteria, here we performed a systemically comparative analysis of anticancer efficacy and toxicity of VNP20009 administered: (i) orally at a dose of 1 x 10(9) cfu/mouse (VNP9-oral); (ii) intraperitoneally at a dose of 1 x 10(4) cfu/mouse (VNP4-i.p.); or (iii) intraperitoneally at a dose of 1 x 10(6) cfu/mouse in tumor-free and tumor-bearing murine models. The results showed that VNP9-oral, similar to VNP4-i.p., induced significant tumor growth inhibition whereas VNP6-i.p. induced better anticancer effect in the B16F10 melanoma model. Among three treatments, VNP9-oral induced the mildest and reversible toxicity whereas VNP6-i.p. resulted in the most serious and irreversible toxicities when compared to other two treatments. Moreover, the combination of VNP9-oral with a low dose of chemotherapeutics produced comparable antitumor effects but displayed significantly reduced toxicity when compared to VNP6-i.p. The findings demonstrated that oral administration, as a novel avenue in the application of bacteria, is highly safe and effective. Moreover, the present preclinical study should facilitate the optimization of bacterial therapies with improved anticancer efficacy and reduced adverse effects in future clinical trials.
Asunto(s)
Vacunas Bacterianas/administración & dosificación , Neoplasias Experimentales/terapia , Salmonella typhimurium/inmunología , Administración Oral , Animales , Vacunas Bacterianas/toxicidad , Citocinas/biosíntesis , Femenino , Melanoma Experimental/terapia , Ratones , Ratones Endogámicos C57BL , Neoplasias Experimentales/inmunologíaRESUMEN
Botulinum neurotoxins are the most potent toxins known and causative agents of human botulism. Treatment comprises of administering purified polyclonal antitoxin or the prophylactic use of a vaccine containing formaldehyde inactivated toxoid. Whilst formaldehyde inhibits toxin activity, it induces so many structural changes in the molecule that immunisation often results in low levels of neutralising antibodies. We describe here for the first time a simple, less time consuming, novel method for producing a non-toxic toxoid that is structurally and antigenically more similar to the native toxin. Toxin is chemically inactivated by alkylation with iodoacetamide in the presence of reversibly denaturing conditions. This reduces neurotoxic activity by at least 7-orders of magnitude to undetectable levels. Following immunisation, in vivo neutralising antibody levels were 600-times higher than those produced with formaldehyde toxoid, despite generating equivalent ELISA antitoxin binding titres. These studies demonstrate that the new toxoid retains more of the native toxins structure and critical epitopes responsible for inducing life-saving neutralising antibody. Toxoid produced by the new method should substantially improve both antitoxin and vaccine production and be applicable to other toxins and immunogens.
Asunto(s)
Vacunas Bacterianas/inmunología , Antitoxina Botulínica/inmunología , Toxinas Botulínicas/inmunología , Toxoides/inmunología , Alquilantes/química , Alquilación , Animales , Anticuerpos Antibacterianos/sangre , Vacunas Bacterianas/química , Vacunas Bacterianas/toxicidad , Antitoxina Botulínica/química , Antitoxina Botulínica/toxicidad , Toxinas Botulínicas/química , Toxinas Botulínicas/toxicidad , Toxinas Botulínicas Tipo A , Reactivos de Enlaces Cruzados/química , Ensayo de Inmunoadsorción Enzimática , Femenino , Formaldehído/química , Yodoacetamida/química , Dosificación Letal Mediana , Masculino , Ratones , Ratones Endogámicos BALB C , Unión Neuromuscular/efectos de los fármacos , Pruebas de Neutralización , Parálisis/inducido químicamente , Conformación Proteica , Desnaturalización Proteica , Factores de Tiempo , Toxoides/química , Toxoides/toxicidad , Vacunas de Productos Inactivados/inmunologíaRESUMEN
Coxiella burnetii is a highly infectious obligate intracellular bacterium. The phase I form is responsible for Q fever, a febrile illness with flu-like symptoms that often goes undiagnosed. The attenuated C. burnetii phase II (having a truncated "O" chain of its lipopolysaccharide) does not cause disease in immunocompetent animals; however, phase II organisms remain infectious, and we questioned whether disease could be produced in immunodeficient mice. To study C. burnetii phase II infections, febrile responses in gamma interferon knockout (IFN-gamma(-/-)), BALB/c, Toll-like receptor 2 knockout (TLR2(-/-)), and C57BL/6 mice were measured using the Nine Mile phase II (NMII) strain of C. burnetii. Immunocompetent mice showed minimal febrile responses, unlike those obtained with IFN-gamma(-/-) and TLR2(-/-) mice, which showed elevated rectal temperatures that were sustained for approximately 15 days with transient increases in splenic weights. Reinfection of IFN-gamma(-/-) and TLR2(-/-) mice with C. burnetii NMII 30 days after primary infection protected mice as evident by reduced febrile responses and a lack of splenic inflammation. Although minimal detection of Coxiella in TLR2(-/-) mouse spleens was observed, greater colonization was evident in the IFN-gamma(-/-) mice. Cytokine analysis was performed on infected peritoneal macrophages isolated from these mice, and immunocompetent macrophages showed robust tumor necrosis factor alpha, IFN-gamma, and granulocyte-macrophage colony-stimulating factor (GM-CSF) but no interleukin-12 (IL-12) responses. IFN-gamma(-/-) macrophages produced elevated levels of IL-6, IL-10, and IL-12, while TLR2(-/-) macrophages produced GM-CSF, IL-12, and minimal IL-10. To distinguish immunity conferred by innate or adaptive systems, adoptive transfer studies were performed and showed that immune lymphocytes obtained from immunocompetent mice protected against a subsequent challenge with NMII, indicating that adaptive immunity mediates the observed protection. Thus, our data show that NMII is capable of eliciting disease in immunocompromised mice, which may help in evaluation of vaccine candidates as well as the study of host-pathogen interactions.
Asunto(s)
Vacunas Bacterianas/toxicidad , Coxiella burnetii/inmunología , Interferón gamma/inmunología , Macrófagos Peritoneales/microbiología , Fiebre Q/etiología , Receptor Toll-Like 2/inmunología , Animales , Linfocitos B/inmunología , Vacunas Bacterianas/inmunología , Chlorocebus aethiops , Coxiella burnetii/patogenicidad , Citocinas/inmunología , Femenino , Huésped Inmunocomprometido , Inmunoglobulina G/inmunología , Interferón gamma/deficiencia , Macrófagos Peritoneales/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados , Fiebre Q/inmunología , Fiebre Q/microbiología , Esplenomegalia/microbiología , Linfocitos T/inmunología , Receptor Toll-Like 2/metabolismo , Vacunas Atenuadas/inmunología , Vacunas Atenuadas/toxicidad , Células VeroRESUMEN
Data on influence of Francisella tularensis C-complex preparations on formation of immunity against tularemia are presented. Study of cellular immunity characteristics as well as dynamics of antibody response was carried out on white mice and guinea pigs models. Absence of toxicity, pyrogenicity, and negative effects on immunocompetent cells in combination with protective activity points to possibility of use the C-complex as a component of a subunit vaccine.
Asunto(s)
Vacunas Bacterianas/inmunología , Francisella tularensis/inmunología , Tularemia/inmunología , Tularemia/prevención & control , Vacunación , Animales , Anticuerpos Antibacterianos/sangre , Apoptosis , Proteínas Bacterianas/inmunología , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/toxicidad , Células Cultivadas , Evaluación Preclínica de Medicamentos , Cobayas , Activación de Linfocitos , Proteínas de la Membrana/inmunología , Ratones , Bazo/fisiología , Timo/fisiología , Tularemia/sangre , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/toxicidadRESUMEN
A vaccine inducing protection against most of the circulating variants of serogroup B meningococcal strains is not yet available. A number of plausible options are currently under investigation. A conjugate vaccine based on a modified capsular polysaccharide might well work, but has safety concerns from molecular mimicry between group B sialic acid and human tissue. Recently, however, the group B capsule has been shown to contain de-N-acetyl sialic acid residues that do not cross react with normal host tissues and can then be the target of bactericidal antibodies. Potentially, this polysaccharide structure could form the basis of a safe and protective group B vaccine. Outer membrane vesicles (OMVs) from Neisseria lactamica avoid the immunodominant and highly strain specific immune response against the PorA protein, and are reported to elicit cross reactive protection in mice against lethality from challenge with meningococcal group B bacteria. However, the serum antibody responses lack bactericidal activity, and the mechanisms of protection are unknown. A number of universal, cross-reactive antigens have been identified through "reverse vaccinology" and successfully tested as recombinant protein vaccines. Promising results have also been demonstrated using OMV vaccines prepared from strains engineered for upregulation of conserved, cross-reactive antigens. This approach takes advantage of experience gained with conventional wild-type OMV vaccines and the large number of new antigens identified through sequencing the genome of N. meningitidis. Initial studies show that the traditional use of detergents to decrease toxicity by extraction of lipopolysaccharides (LPS) should, if possible, be omitted in order to avoid extraction of important lipoproteins. In the absence of detergent extraction, clinical OMV formulations with acceptable toxicity may still be achieved by constructing vaccine production strains with genetically detoxified LPS. Thus, a MenB vaccine might be designed based on non-cross-reactive capsular antigens, OMV vaccines from genetically modified strains, recombinant proteins or a combination of these approaches. Given all of the recent data available and experience gained, the possibility for development of a universal vaccine for prevention of group B meningococcal disease looks promising. For evaluation of vaccine formulations relying on cross-reactive proteins, selection of strains for representation of the global epidemiological situation will be of outmost importance. Defining criteria for establishing and revising such strain collections is currently ongoing and will be a key element in developing and evaluating new protein based vaccines in the time to come.
Asunto(s)
Anticuerpos Antibacterianos/biosíntesis , Antígenos Bacterianos/inmunología , Infecciones Meningocócicas/prevención & control , Vacunas Meningococicas/administración & dosificación , Neisseria meningitidis Serogrupo B/inmunología , Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/toxicidad , Complemento C3b/metabolismo , Humanos , Infecciones Meningocócicas/inmunología , Vacunas Meningococicas/inmunologíaRESUMEN
Single-stranded RNA stimulates immune cells and induces the secretion of pro-inflammatory cytokines and type I IFN. As adjuvant RNA can induce a T(h)2 type of humoral response, however, its potency in the induction of cytotoxic T cells in vivo has not been analyzed. Here we show that immunization with the antigen ovalbumin (OVA) and the adjuvant phosphodiester RNA complexed to the cationic lipid N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) induced a Toll-like receptor-7-dependent cytotoxic T cell and humoral response. Staining with SIINFEKL-K(b) tetramers demonstrated the induction of antigen-specific T cells that were functional in in vivo cytotoxic T cell assays against SIINFEKL-loaded target cells. In infection experiments with OVA-secreting Listeria monocytogenes, the cytotoxic T cell response strongly reduced the bacterial load in liver and spleen. The RNA-driven humoral response was characterized by OVA-specific antibodies of the IgG1 isotype whereas CpG-DNA induced antigen-specific antibodies of the IgG2a (BALB/c) or IgG2c (C57BL/6) isotype. Furthermore, stimulation with RNA did not induce splenomegaly, a common feature of CpG-DNA-driven immune activation in mice. Taken together, our data confirm that RNA can be used as a safe adjuvant and induces a strong antibody response of the IgG1 isotype. Additionally, we demonstrate that RNA induces an antigen-specific immunity characterized by a potent cytotoxic T cell response to infection.
Asunto(s)
Adyuvantes Inmunológicos , Vacunas Bacterianas/inmunología , Listeria monocytogenes/inmunología , Glicoproteínas de Membrana/inmunología , Oligonucleótidos/inmunología , ARN/inmunología , Linfocitos T Citotóxicos/inmunología , Receptor Toll-Like 7/inmunología , Adyuvantes Inmunológicos/toxicidad , Animales , Formación de Anticuerpos , Antígenos/inmunología , Vacunas Bacterianas/toxicidad , Células Cultivadas , Modelos Animales de Enfermedad , Ácidos Grasos Monoinsaturados/inmunología , Femenino , Inmunización , Inmunoglobulina G/sangre , Listeriosis/inmunología , Listeriosis/prevención & control , Activación de Linfocitos , Glicoproteínas de Membrana/deficiencia , Glicoproteínas de Membrana/genética , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados , Oligodesoxirribonucleótidos/inmunología , Oligonucleótidos/toxicidad , Ovalbúmina/inmunología , Compuestos de Amonio Cuaternario/inmunología , ARN/toxicidad , Células Th2/inmunología , Receptor Toll-Like 7/deficiencia , Receptor Toll-Like 7/genéticaRESUMEN
Avian botulism is a paralytic disease caused by a toxin produced by Clostridium botulinum type C. Since type C isolates from cases of avian botulism produced a neurotoxin consisting of a mosaic form of parts of type C and D neurotoxins, we examined the antitoxin titers in the convalescent sera of botulism-affected birds which belonged to family Anatidae. ELISA using the C/D mosaic neurotoxin as an antigen revealed that the antibody was detected in the sera at 2 weeks, but not at 5 weeks after the onset, suggesting that the antibody only appeared for a short period in the convalescent phase. However, we failed to detect the antibody titers with anti-chicken IgG instead of anti-duck IgG. We therefore examine the immunological properties of IgG among different families and species. The results revealed that different species of IgG in the same family exhibited strong cross-reactivity. Ducks immunized once with the toxoid together with a commercial oil-adjuvanted vaccine were found to develop sufficient antibody to protect against a challenge with a lethal toxin dose. The ELISA titers did not correspond to the neutralization titers in the sera of immunized ducks at the early stage during immunization. These findings suggest that the neutralizing titer was more useful than the ELISA titer for evaluating the protection against the toxin, but the ELISA technique may be applicable for detecting the occurrence of botulism.
Asunto(s)
Vacunas Bacterianas/inmunología , Toxinas Botulínicas/inmunología , Botulismo/veterinaria , Patos/inmunología , Enfermedades de las Aves de Corral/inmunología , Enfermedades de las Aves de Corral/prevención & control , Animales , Anticuerpos Antibacterianos/sangre , Vacunas Bacterianas/toxicidad , Botulismo/prevención & control , Patos/microbiología , Inmunoglobulina G/sangre , Dosificación Letal Mediana , RatonesRESUMEN
The safety and immunological activity of P. aeruginosa vaccine were experimentally evaluated. The vaccine was prepared on the basis of the antigens of P. aeruginosa extracellular slime which was accumulated in medium K-4, obtained with the use of original technology. The immunization of animals with P. aeruginosa vaccine induced the synthesis of antibodies. The introduction of the vaccine in 2 or 3 injections resulted in a high level of antibody formation, differing with the use of various strains. Hyperimmune sera, obtained by the multiple immunization of rabbits with P. aeruginosa vaccine, ensured high protection of mice from P. aeruginosa infection. The vaccine proved to be safe when evaluated in experiments of acute and chronic toxicity, made on laboratory animals.
Asunto(s)
Antígenos Bacterianos/inmunología , Vacunas Bacterianas/administración & dosificación , Infecciones por Pseudomonas/prevención & control , Pseudomonas aeruginosa/inmunología , Vacunación , Animales , Anticuerpos Antibacterianos/biosíntesis , Especificidad de Anticuerpos , Antígenos Bacterianos/toxicidad , Vacunas Bacterianas/aislamiento & purificación , Vacunas Bacterianas/toxicidad , Medios de Cultivo , Hidroxilamina , Inyecciones Subcutáneas , Ratones , Infecciones por Pseudomonas/inmunología , Pseudomonas aeruginosa/crecimiento & desarrollo , ConejosRESUMEN
The inhalation of aerozolized botulinum toxin may represent a potential significant hazard to both military and civilian personnel. Since the lung is the primary target organ for inhaled toxin, the investigation reported herein was conducted to examine lung function in mice exposed to botulinum toxin A complex by intranasal route. Data includes lethality, symptomatology, measurement of respiratory function (minute ventilation, respiratory frequency, and tidal volume), and histopathology of the lungs. The clinical signs of intoxication are similar to those observed in foodborne botulism. Plethysmography revealed severe impairment of all respiratory parameters tested from 7 hours postexposure. Severe lung lesions, possibly secondary to the intoxication, were observed in mice who survived 14 days after the toxin challenge. These included intra-alveolar hemorrhage and interstitial edema. Mice immunized by the pentavalent (ABCDE) toxoid were protected against the neurotoxin (4 LD50) as revealed by the decrease of lethality and severity of nervous signs of intoxication, but not against histopathological changes in the lungs. These effects are nonspecific and require further experiments in order to specify the relationships between the pathology and the inflammatory process in the lung due to mediators such as cytokines,and possibly permanent physiological sequelae.
Asunto(s)
Administración Intranasal , Vacunas Bacterianas/inmunología , Toxinas Botulínicas Tipo A/toxicidad , Pulmón/efectos de los fármacos , Toxoides/inmunología , Animales , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/toxicidad , Conducta Animal/efectos de los fármacos , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/antagonistas & inhibidores , Toxinas Botulínicas Tipo A/inmunología , Relación Dosis-Respuesta a Droga , Dosificación Letal Mediana , Locomoción/efectos de los fármacos , Pulmón/patología , Pulmón/fisiopatología , Masculino , Ratones , Ratones Endogámicos BALB C , Pletismografía , Ventilación Pulmonar/efectos de los fármacos , Respiración/efectos de los fármacos , Volumen de Ventilación Pulmonar/efectos de los fármacos , Factores de Tiempo , Toxoides/administración & dosificación , Toxoides/toxicidadRESUMEN
OBJECTIVE: To construct a genetically modified nontoxigenic Pasteurella multocida toxin (PMT) and examine its immunoprotective activity against challenge exposure with wild-type PMT in pigs. ANIMALS: 5 healthy pigs. PROCEDURE: A nontoxigenic PMT was created by replacing the serine at position 1164 with alanine (S1164A) and the cysteine at position 1165 with serine (C1165S). Toxic activity was determined by use of the guinea pig skin test and mouse lethality test. Three pigs were vaccinated twice with the modified PMT, and the remaining 2 pigs served as nonvaccinated control animals. Vaccinated and control pigs were challenge exposed with wild-type PMT. Pigs were euthanatized and necropsied on day 14 after challenge exposure. Turbinate atrophy was examined macroscopically and assigned a score. Serum anti-PMT antibodies were determined by use of an ELISA. RESULTS: The genetically modified PMT was characterized by a total lack of toxic activity. Pigs vaccinated with the modified PMT became seropositive; in contrast, control pigs remained seronegative. Necropsy revealed that the 2 control pigs had moderate and severe turbinate atrophy, respectively, whereas the 3 vaccinated pigs did not have any lesions in the turbinates or abnormalities in other organs. CONCLUSIONS AND CLINICAL RELEVANCE: Modification by use of S1164A and C1165S leads to a complete loss of toxic effects of PMT without impairment of the ability to induce protective immunity in pigs. Analysis of these results suggests that genetically modified PMT may represent a good candidate for use in developing a vaccine against progressive atrophic rhinitis in pigs.